" /> Carboplatin/Paclitaxel/Trastuzumab Regimen - CISMeF





Preferred Label : Carboplatin/Paclitaxel/Trastuzumab Regimen;

NCIt synonyms : Carboplatin-Paclitaxel-Trastuzumab; Carboplatin/Paclitaxel/Trastuzumab; Carboplatin-Paclitaxel-Trastuzumab Regimen; TPC; TCH; Paclitaxel/Carboplatin/Trastuzumab; Carboplatin/Paclitaxel Plus Trastuzumab Regimen; Paclitaxel/Carboplatin Plus Trastuzumab;

NCIt related terms : Carboplatin and Paclitaxel (CP) and Trastuzumab; Carboplatin and Paclitaxel (CP) and Trastuzumab-herw; Carboplatin and Paclitaxel (CP) and Trastuzumab-dttb; Carboplatin and Paclitaxel (CP) and Trastuzumab-qyyp; Carboplatin and Paclitaxel (CP) and Trastuzumab-pkrb; Carboplatin and Paclitaxel (CP) and Trastuzumab-zerc; Carboplatin and Paclitaxel (CP) and Trastuzumab-anns; Carboplatin and Paclitaxel (CP) and Trastuzumab-dkst; Carboplatin and Paclitaxel (CP) and Trastuzumab-strf;

NCIt definition : A regimen consisting of paclitaxel, carboplatin and trastuzumab that may be used as a treatment for breast, esophageal and esophagogastric junction, and gastric cancers and endometrial carcinoma.;

NCIt note : Source: NCCN Guidelines 2017;

NCI Metathesaurus CUI : CL525001;

Codes from synonyms : 59563; 129449; 129061; 128964; 128867; 129352; 129255; 129158; 139844;

Détails


Position du mot-clé dans l'(les) arborescence(s) : arborescence

Vous pouvez consulter :


Nous contacter.
29/07/2025


[Accueil] [Haut de page]

© CHU de Rouen. Toute utilisation partielle ou totale de ce document doit mentionner la source.